Incyte (INCY) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Incyte (INCY) Tops Q4 EPS by 20c
February 12, 2016 8:57 AM EST
UBS analyst, Matthew Roden, looked through a good quarter for Incyte (NASDAQ: INCY) to the importance of pipeline growth. He adjusted his model to remove the contribution of Jakafi in solid tumors which led him to cut his PT to $88 from $110. No change to the Buy rating though as the new PT implies 35% upside.
Although 4Q operations beat cleanly on the top/bottom lines, 2016 opex guidance and in particular the failure of Jakafi in solid tumors caused a PT cut to $88 (from $110) as solid tumors (and '110) are removed from the model. Risk-adjusted... More
February 11, 2016 6:46 AM EST
Incyte Corporation (Nasdaq: INCY) announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.
Following these results, and the... More
